Navire Pharma

Executive Summary

Navire Pharma is a clinical-stage biotechnology company developing novel small molecule inhibitors targeting SHP2, a key node in cancer signaling pathways. Its lead program aims to overcome resistance mechanisms in difficult-to-treat cancers, with potential as both monotherapy and combination therapy. Based in San Francisco, the company is advancing its pipeline through internal development and strategic collaborations. With a focus on precision oncology, Navire's SHP2 inhibitors could address significant unmet needs, particularly in tumors driven by RTK/RAS/MAPK pathway alterations. The company's clinical-stage asset is currently in Phase 1, and upcoming milestones include initial efficacy data and potential partnership announcements.

Upcoming Catalysts (preview)

• Q1 2026Phase 1 dose-escalation data readout for lead SHP2 inhibitor70% success
• H1 2026Announcement of strategic partnership or co-development deal50% success
• Q2 2026IND filing for second-generation SHP2 inhibitor60% success